David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

The Second Half of 2021 Should Be Much Easier for Zomedica Investors

By David Moadel, InvestorPlace Contributor

So far, it hasn't been easy to stay the course with ZOM stock. Q3 and Q4 developments, however, should lift the shareholders' spirits.

Newegg Has Value Far Beyond Its Meme-Stock Status

By David Moadel, InvestorPlace Contributor

Newegg now accepts at least three popular digital tokens. The company's a pioneer, and NEGG stock has value far beyond its meme-stock status.

Venture Into the Metaverse with a Stake in Roblox

By David Moadel, InvestorPlace Contributor

RBLX stock hasn't been an outstanding performer in 2021 so far, but the best times could be coming as Roblox partners with a major tech firm.

This Downturn in Baidu Stock Isn’t a Problem, It’s an Opportunity

By David Moadel, InvestorPlace Contributor

As BIDU stock hovers near short-term lows, prospective investors should seize the opportunity in light of impressive quarterly fiscal stats.

Updated Clinical and Financial Data Make the Case for CRISPR Therapeutics

By David Moadel, InvestorPlace Contributor

Looking for a terrific value in the biotechnology space? It doesn't get much better than CRSP stock, which just entered a buy zone.

Load More